384 related articles for article (PubMed ID: 25712626)
1. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
2. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib: first global approval.
Markham A
Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
[TBL] [Abstract][Full Text] [Related]
12. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S
J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176
[TBL] [Abstract][Full Text] [Related]
13. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
14. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
15. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD
Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib may have the potential to increase radiotherapy side effects.
Gryc T; Putz F; Goerig N; Ziegler S; Fietkau R; Distel LV; Schuster B
Radiat Oncol; 2017 Jun; 12(1):109. PubMed ID: 28659152
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
Bird ST; Tian F; Flowers N; Przepiorka D; Wang R; Jung TH; Kessler Z; Woods C; Kim B; Miller BW; Wernecke M; Kim C; McKean S; Gelperin K; MaCurdy TE; Kelman JA; Graham DJ
JAMA Oncol; 2020 Feb; 6(2):248-254. PubMed ID: 31855259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]